Display options
Cite
Slatter TL, Wilson M, Tang C, et al. Antitumor cytotoxicity induced by bone-marrow-derived antigen-presenting cells is facilitated by the tumor suppressor protein p53 via regulation of IL-12. Oncoimmunology. 2015;5(3):e1112941doi: 10.1080/2162402X.2015.1112941.
Slatter, T. L., Wilson, M., Tang, C., Campbell, H. G., Ward, V. K., Young, V. L., Van Ly, D., Fleming, N. I., Braithwaite, A. W., & Baird, M. A. (2016). Antitumor cytotoxicity induced by bone-marrow-derived antigen-presenting cells is facilitated by the tumor suppressor protein p53 via regulation of IL-12. Oncoimmunology, 5(3), e1112941. https://doi.org/10.1080/2162402X.2015.1112941
Slatter, Tania L, et al. "Antitumor cytotoxicity induced by bone-marrow-derived antigen-presenting cells is facilitated by the tumor suppressor protein p53 via regulation of IL-12." Oncoimmunology vol. 5,3 (2016): e1112941. doi: https://doi.org/10.1080/2162402X.2015.1112941
Slatter TL, Wilson M, Tang C, Campbell HG, Ward VK, Young VL, Van Ly D, Fleming NI, Braithwaite AW, Baird MA. Antitumor cytotoxicity induced by bone-marrow-derived antigen-presenting cells is facilitated by the tumor suppressor protein p53 via regulation of IL-12. Oncoimmunology. 2015 Dec 17;5(3):e1112941. doi: 10.1080/2162402X.2015.1112941. eCollection 2016 Mar. PMID: 27141366; PMCID: PMC4839352.
Copy Download .nbib Format: NLM
Share it on

Oncoimmunology. 2015 Dec 17;5(3):e1112941. doi: 10.1080/2162402X.2015.1112941. eCollection 2016 Mar.

Antitumor cytotoxicity induced by bone-marrow-derived antigen-presenting cells is facilitated by the tumor suppressor protein p53 via regulation of IL-12.

Oncoimmunology

Tania L Slatter, Michelle Wilson, Chingwen Tang, Hamish G Campbell, Vernon K Ward, Vivienne L Young, David Van Ly, Nicholas I Fleming, Antony W Braithwaite, Margaret A Baird

Affiliations

  1. Department of Pathology, Dunedin School of Medicine, University of Otago , Dunedin, New Zealand.
  2. Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand; Department of Microbiology and Immunology, School of Medical Sciences, University of Otago, Dunedin, New Zealand.
  3. Department of Microbiology and Immunology, School of Medical Sciences, University of Otago , Dunedin, New Zealand.
  4. Children's Medical Research Institute, University of Sydney , Westmead, Australia.
  5. Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand; Children's Medical Research Institute, University of Sydney, Westmead, Australia; Maurice Wilkins Center, Auckland, New Zealand.
  6. Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand; Maurice Wilkins Center, Auckland, New Zealand.

PMID: 27141366 PMCID: PMC4839352 DOI: 10.1080/2162402X.2015.1112941

Abstract

Activated antigen-presenting cells (APC) deliver the three signals cytotoxic T cells require to differentiate into effector cells that destroy the tumor. These comprise antigen, co-stimulatory signals and cytokines. Once these cells have carried out their function, they apoptose. We hypothesized that the tumor suppressor protein, p53, played an important role in generating the antitumor response facilitated by APC. CD11c

Keywords: Cytotoxic immune response; dendritic cells; interleukin 12; p53 tumor suppressor protein; tumor vaccination

References

  1. Nature. 2014 Nov 27;515(7528):563-7 - PubMed
  2. J Exp Med. 2003 Aug 18;198(4):615-21 - PubMed
  3. Proc Natl Acad Sci U S A. 1994 Mar 15;91(6):2026-30 - PubMed
  4. Genes Cancer. 2011 Apr;2(4):503-16 - PubMed
  5. Immunity. 2013 Jul 25;39(1):38-48 - PubMed
  6. J Exp Med. 2003 May 5;197(9):1141-51 - PubMed
  7. Nature. 1993 Apr 29;362(6423):849-52 - PubMed
  8. Annu Rev Immunol. 2013;31:563-604 - PubMed
  9. Cancer Immunol Immunother. 2012 Mar;61(3):373-84 - PubMed
  10. Carcinogenesis. 2005 Jul;26(7):1161-9 - PubMed
  11. Acta Diabetol. 2013 Dec;50(6):899-906 - PubMed
  12. Nature. 1993 Apr 29;362(6423):847-9 - PubMed
  13. J Immunol. 2002 Jun 1;168(11):5521-9 - PubMed
  14. Immunity. 2014 May 15;40(5):681-91 - PubMed
  15. Cancer Immunol Immunother. 2007 Sep;56(9):1485-99 - PubMed
  16. Cell. 1994 Aug 26;78(4):703-11 - PubMed
  17. Immunity. 2004 Aug;21(2):279-88 - PubMed
  18. Immunity. 2015 Jun 16;42(6):1197-211 - PubMed
  19. Gene Ther. 2008 Oct;15(19):1321-9 - PubMed
  20. J Immunol. 2012 Sep 1;189(5):2151-8 - PubMed
  21. Mol Cell. 2014 Dec 4;56(5):617-29 - PubMed
  22. Cell Death Differ. 2003 Apr;10(4):431-42 - PubMed
  23. J Immunol. 2002 Sep 15;169(6):3006-14 - PubMed
  24. J Immunother. 2012 Nov-Dec;35(9):670-9 - PubMed
  25. J Immunol. 2010 Jul 15;185(2):795-802 - PubMed
  26. Nat Rev Clin Oncol. 2014 May;11(5):260-71 - PubMed
  27. Am J Hematol. 2007 Oct;82(10):924-8 - PubMed
  28. Immunity. 1997 Jun;6(6):715-26 - PubMed
  29. Cell Death Differ. 2010 Mar;17(3):540-50 - PubMed
  30. J Immunol. 2010 Aug 15;185(4):2125-33 - PubMed
  31. Immunol Rev. 2010 Jul;236:11-27 - PubMed
  32. J Exp Med. 2000 Dec 18;192(12):1685-96 - PubMed
  33. J Immunol. 2000 Dec 15;165(12):6762-70 - PubMed
  34. Hum Immunol. 2012 Apr;73(4):342-5 - PubMed
  35. Science. 1997 Nov 28;278(5343):1623-6 - PubMed
  36. Science. 2006 Feb 24;311(5764):1160-4 - PubMed
  37. J Immunol. 2009 Nov 15;183(10 ):6282-95 - PubMed
  38. J Immunol. 2001 May 1;166(9):5448-55 - PubMed
  39. Blood. 2001 Mar 1;97(5):1474-82 - PubMed
  40. J Immunol. 2007 Dec 1;179(11):7577-84 - PubMed
  41. Nature. 2014 Nov 27;515(7528):577-81 - PubMed
  42. Curr Opin Immunol. 2014 Apr;27:26-32 - PubMed
  43. Immunol Cell Biol. 2011 Aug;89(6):681-8 - PubMed
  44. Int J Cancer. 2004 Apr 20;109(4):499-506 - PubMed

Publication Types